Healthcare stocks are lower today with the NYSE Healthcare
Sector Index slipping about 0.5% and shares of healthcare companies
in the S&P 500 declining about 0.6% as a group.
In company news, Pacific Biosciences (
) is up more than 80% at $6.23 a share, earlier establishing a new
52-week high of $6.50 after announcing a new agreement with Roche
Holding Ltd.'s (
) diagnostics unit to develop new products including sequencing
systems and consumables.
The new products would be based on PACB's single molecule,
real-time technology with RHHBY obtaining exclusive worldwide
rights to any products developed for human in-vitro
PACB will continue to market all of its current and future
products for fields outside of human in-vitro diagnostics,
including research, plant, animal, and applied markets.
In other sector news,
(+) DVAX, Reports immunogenicity and safety results of two Phase
III trials of its Heplisav investigational hepatitis B vaccine,
concluding the drug can be "an important new adjuvant for
immunization against hepatitis B."
(-) CLVS, Bloomberg reports the biotech company is struggling to
find a buyer. CLVS previously hired Credit Suisse to shore up
interest in an acquisition.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.